Skip to main content
. 2020 Dec 10;14:544431. doi: 10.3389/fncel.2020.544431

Figure 4.

Figure 4

PK11195 or Midazolam down-regulated NLRP3 inflammasome and its downstream IL-1β and IL-18 in the reactivity of BV2 microglia cell. BV2 microglial cells were activated by LPS. LPS, priming stimuli, induce mitochondria to release ROS and then regulate NLRP3 inflammasome activation. ATP, an activation signal, triggers the specific activation of NLRP3. Finally, the cleaved-caspase-1 activates the IL-1β and IL-18. Both pretreatment and post-treatment with TSPO ligand can inhibit the activation of NLRP3 inflammasome and IL-1β and IL-18 expression. Collectively, these results indicate that TSPO ligands are promising targets to control microglial reactivity and neuroinflammatory diseases.